Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach.
To learn more about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.
Through a series of exclusive interviews with world-renowned scientists and bioethicists, Technology Networks Explores the CRISPR Revolution will investigate the ground-breaking research taking place in the CRISPR space, CRISPR "controversies" and whether the CRISPR technology looks set to fulfil its promise of revolutionizing science.Read More
To learn how Campylobacter hides from the body’s immune system, why some people are more susceptible than others, and the potential role that carbohydrate-based diagnostics could play in the fight against the bacterium, we spoke to Professor Rob Field, Co-founder of Iceni Diagnostics.Read More
Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.
Technology Networks recently spoke with Professor Jürgen Cox to learn more about the computational software tools his laboratory are developing, and how 4D proteomics workflows enhance research in clinical proteomics.Read More
Digitization is a trend threading many disciplines, and lateral flow is no exception. Here, we share insights from Dave Taylor, co-founder and chief operating officer of Bond Digital Health, a UK-based life sciences company that develops app and cloud technology solutions for lateral flow diagnostics.Read More
10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.Read More
We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.Read More